Candriam S.C.A. Acquires New Position in Hims & Hers Health, Inc. $HIMS

Candriam S.C.A. acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 88,780 shares of the company’s stock, valued at approximately $4,426,000.

Other institutional investors also recently modified their holdings of the company. Nuveen LLC acquired a new stake in Hims & Hers Health during the first quarter valued at $58,403,000. CloudAlpha Capital Management Limited Hong Kong purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth about $20,580,000. State of Michigan Retirement System lifted its holdings in shares of Hims & Hers Health by 84.9% during the 2nd quarter. State of Michigan Retirement System now owns 1,379,100 shares of the company’s stock valued at $68,748,000 after buying an additional 633,300 shares during the last quarter. Jump Financial LLC grew its stake in shares of Hims & Hers Health by 633.2% in the 1st quarter. Jump Financial LLC now owns 725,445 shares of the company’s stock valued at $21,437,000 after buying an additional 626,496 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Hims & Hers Health by 19.5% in the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock worth $71,969,000 after buying an additional 397,310 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,592 shares of the firm’s stock in a transaction on Friday, October 17th. The shares were sold at an average price of $57.13, for a total value of $662,250.96. Following the sale, the chief financial officer owned 70,232 shares in the company, valued at approximately $4,012,354.16. This trade represents a 14.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael Chi sold 900 shares of the company’s stock in a transaction on Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the transaction, the insider owned 291,439 shares of the company’s stock, valued at approximately $16,976,321.75. The trade was a 0.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 712,336 shares of company stock valued at $37,611,319 in the last 90 days. 13.71% of the stock is currently owned by insiders.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $37.09 on Friday. The company has a market capitalization of $8.44 billion, a PE ratio of 68.68, a price-to-earnings-growth ratio of 7.36 and a beta of 2.20. Hims & Hers Health, Inc. has a one year low of $19.15 and a one year high of $72.98. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company’s fifty day moving average price is $50.63 and its 200 day moving average price is $51.33.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm’s revenue was up 49.2% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Needham & Company LLC reaffirmed a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. KeyCorp began coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating for the company. BTIG Research restated a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Truist Financial reduced their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and an average target price of $45.27.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.